Roche writes off ul­cer­a­tive col­i­tis por­tion of etrolizum­ab pro­gram, days af­ter dis­sect­ing PhI­II set­back

Af­ter dis­ap­point­ing Phase III read­outs all but dec­i­mat­ed Roche’s ex­pec­ta­tions for etrolizum­ab as an ul­cer­a­tive col­i­tis treat­ment, the phar­ma gi­ant is bury­ing the pro­gram in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER